Insilico Medicine Announces Positive Topline Results of the New Zealand Phase I Trial of INS018_055, an AI-Designed Drug for an AI-Discovered Target in Idiopathic Pulmonary Fibrosis (IPF)

On January 10, 2023, Insilico Medicine, a clinical-stage artificial intelligence (AI)-driven drug R&D company, announced positive topline results of safety, tolerability, and pharmacokinetics (PK) from the Phase I clinical trial of INS018_055, a potential first-in-class drug discovered by Insilico's end-to-end AI platform for idiopathic pulmonary fibrosis (IPF). "Topline data from our Phase 1 study of INS018_055 demonstrate the ability of our Pharma.AI platform to discover novel targets and design novel molecules with a high level of translatability to human biology,” said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine. “This lead program is paving the way for a new era of drug discovery and development that utilizes next-generation AI to identify novel targets and generate novel drugs to treat diseases requiring regular peroral drug administration for the entire lifetime with very high safety requirements.” 

Login Or Register To Read Full Story